Eray Tunce

Eray Tunce

Auto-generated profile, based on publicly available information

Eray Tunce

Department of Pediatric Rheumatology, Ümraniye Training and Research Hospital, University of Health Sciences, İstanbul, Turkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Rheumatology
Verified
Journal Article
Closed access
ETEray Tunce
Eray Tunce
SUSıla Atamyıldız Uçar
Sıla Atamyıldız Uçar
MPMerve Cansu Polat
Merve Cansu Polat
ÖGÖzge Altuğ Gücenmez
Özge Altuğ Gücenmez
MÇMustafa Çakan
Mustafa Çakan
BSBetul Sozeri
Betul Sozeri
Objectives: This study aimed to evaluate the predictability of the homozygous M694V genotype in paediatric FMF patients and to develop a clinical scoring system to enhance disease management strategies. Methods: This nationwide, multicentre, cross-sectional study included 3981 paediatric FMF patients with biallelic pathogenic variants in exon 10 of the Mediterranean fever gene. Patients were divided into two groups: group 1 (homozygous M694V) and group 2 (other variants). Data were collected from 37 paediatric rheumatology and/or nephrology clinics across Türkiye, covering patients followed between 2014 and 2023. Results: Group 1 had significantly earlier symptom onset (≤3 years: 49.8% vs 43.9%, P < 0.001) and diagnosis (median age: 5 years vs 5.8 years, P < 0.001) compared with group 2. A higher prevalence of family history of FMF was observed in group 1 (P < 0.001). Clinical manifestations, including arthritis (27.5%), erysipelas-like erythema (ELE) (20.3%) and protracted febrile myalgia syndrome (PFMS) (3.6%), were significantly more frequent in group 1 (P < 0.001 for all). Colchicine resistance was also higher in group 1 (18.1% vs 5.1%, P < 0.001). Logistic regression analysis showed that ≤3 years of age at symptom onset, family history, arthritis, myalgia, PFMS, ELE and splenomegaly were independent predictors of the homozygous M694V genotype. A clinical scoring system was proposed based on these findings. Conclusion: This study provides valuable insights into the clinical predictors of the homozygous M694V genotype in paediatric FMF. The proposed scoring system will support clinicians in prognosis assessment and treatment planning, contributing to improved patient outcomes.

11 March 2025 in Rheumatology
Verified
Journal Article
Closed access
KUKadir Ulu
Kadir Ulu
TCTaner Coşkuner
Taner Coşkuner
GBGülcan Özomay Baykal
Gülcan Özomay Baykal
MYMurat Hakkı Yarar
Murat Hakkı Yarar
RYRamazan Emre Yiğit
Ramazan Emre Yiğit
BSBetul Sozeri
Betul Sozeri
Objective: To assess the phenotypic characteristics of the patients carrying variants of uncertain significance (VUS) in the Mediterranean fever (MEFV) gene. Methods: The study included patients carrying only VUS in the MEFV gene. Patients were excluded if they did not meet the paediatric criteria for familial Mediterranean fever (FMF). Patients were assigned to homozygous, compound heterozygous or heterozygous groups according to their genotype. Additionally, analyses were conducted based on specific genotypes. Results: A total of 2326 MEFV gene records were reviewed. Of these, 310 (F: 152/M: 158) met the inclusion criteria for analysis. The mean age at diagnosis and symptom onset was 7.51 ± 3.9 and 6.03 ± 3.86 years, respectively. Among the patients, 75.5% had a single variant, 17.1% were compound heterozygous, and 7.4% were homozygous. The common VUS alleles accounted for 93% of the cohort: E148Q (65.7%), P369S (15.6%), R408Q (7.6%) and A744S (4.1%). Most cases exhibited mild disease severity, while those with multiple variants were more likely to experience moderate disease severity. Patients with a homozygous allele had a higher mean number of annual attacks (11.2/year), a higher Pras severity score (5.86) and a greater proportion of moderate disease severity (56.5%). The most common clinical manifestations were abdominal pain (90.6%), fever (84.2%) and arthralgia (58.7%). Conclusion: Individuals with VUS variants in the MEFV gene may present with a classic FMF phenotype characterized by mild to moderate disease activity. Patients carrying various VUS genotypes in the MEFV gene exhibit comparable clinical features with some degree of variation.

1 January 2025 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
ETEray Tunce
Eray Tunce
SUSıla Atamyıldız Uçar
Sıla Atamyıldız Uçar
TCTaner Coşkuner
Taner Coşkuner
GBGülcan Özomay Baykal
Gülcan Özomay Baykal
RYRamazan Emre Yiğit
Ramazan Emre Yiğit
BSBetul Sozeri
Betul Sozeri
Objective: The aim of this study was to identify key parameters of a scoring system to be developed to predict the homozygous M694V genotype in patients clinically diagnosed with familial Mediterranean fever. Methods: This study was a cross-sectional analysis of 472 pediatric familial Mediterranean fever patients with a homozygous genotype on exon 10, followed at our tertiary pediatric rheumatology clinic between June 2016 and June 2023. The patients were categorized into 2 groups based on their genotypes: group 1 comprised 402 patients (85.2%) with the homozygous M694V genotype, whereas group 2 consisted of 70 patients (14.8%) with other homozygous genotypes. Demographic information, clinical manifestations, MEFV (Mediterranean fever) gene variant analysis, and treatment responses were recorded from the patients' medical charts. Results: The odds ratios for age at disease onset, arthritis, and chest pain were 0.892 (95% confidence interval [CI]: 0.832–0.958, p = 0.002), 2.565 (95% CI: 1.109–5.934, p = 0.028), and 2.351 (95% CI: 1.123–4.922, p = 0.023), respectively. A total of 60.7% of patients in group 1 had arthralgia, and 25% had erysipelas-like erythema, with these percentages were higher in group 1 compared with group 2 (p = 0.002, p = 0.001, respectively). Protracted febrile myalgia syndrome was detected in 1.5% of patients, all of whom had homozygous M694V genotype. Colchicine resistance was detected in 13.3% of patients, and all had homozygous M694V genotype. Conclusions: This preliminary evaluation identified key parameters for a scoring system designed to predict the homozygous M694V genotype. A multicenter national study will further refine these parameters and develop the scoring system, which will aid clinicians in disease prognosis and therapeutic decision-making.


25 November 2024 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MÇMustafa Çakan
Mustafa Çakan
AAAyşenur Alkaya
Ayşenur Alkaya
LKLütfiye Koru
Lütfiye Koru
BÖBetül Öksel
Betül Öksel
ÖAÖzlem Akgün
Özlem Akgün
NANuray Aktay Ayaz
Nuray Aktay Ayaz

11 February 2025 in Rheumatology
Verified
Journal Article
Closed access
SUSıla Atamyıldız Uçar
Sıla Atamyıldız Uçar
ETEray Tunce
Eray Tunce
BSBetul Sozeri
Betul Sozeri